Company intelligence / Profile preview

Kinexcs

Ownership: Private
Development stage: Commercial

Overview

Kinexcs’ KIMIA Recover product line has received FDA, CE mark, and HSA clearance. It’s commercially deployed in major Singapore hospitals for total knee replacement recovery. The company reports revenue from large implant companies/hospitals and has won awards such as the Johnson & Johnson Quickfire Challenge Award. Clinical results focus on reducing hospital visits/complications while improving at-home patient outcomes.

Therapeutic areas: Rheumatology
Modalities: DeviceDigital therapy platform (Non-pharmacological therapy)Wearable technology
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

KIMIA Recover

Commercial

Indications: Post-surgical knee recovery

Partnerships

Large implant companies/hospitals in Singapore using/deploying KIMIA Recover

Beyond the preview

Go deeper on Kinexcs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinexcs.

Explore the full profile